Summary

The Asia-Pacific calcineurin inhibitors market is expected to reach USD 4.03 billion by 2032 from USD 1.64 billion in 2024, growing with a CAGR of 11.9% in the forecast period of 2024 to 2032.

Market Segmentation:
Asia-Pacific Calcineurin Inhibitors Market, By Drugs (Tacrolimus, Cyclosporine, Pimecrolimus, Voclosporin, and Others), Route of Administeration (Oral, Topical, Parenteral, and Others), Drug type (Branded and Generic), Application (Postoperative Immunosuppression, Atopic Dermatitis, Ulcerative Colitis, Psoriasis, Keratoconjunctivitis, and Others), End user (Hospitals, Specialty Clinics, Home Healthcare, Academic and Research Institutes, and Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, and Others), Country (Japan, China, South Korea, India, Australia, Singapore, Thailand, Malaysia, Indonesia, Vietnam, Philippines, and Rest Of Asia-Pacific) - Industry Trends And Forecast To 2032

Overview of Asia-Pacific Calcineurin Inhibitors Market Dynamics:

Driver
• Rising Prevalence Of Autoimmune Diseases
Restraint

• Limited Efficacy For Long-Term Use Of Calcineurin Inhibitors
Opportunity

• Growing Demand For Personalized Medicine

Market Players:

The key market players operating in the Asia-Pacific calcineurin inhibitors market are listed below:

• Astellas Pharma US, Inc. (U.S.)
• Chunghwa Chemical Synthesis & Biotech Co. Ltd. (Taiwan)
• Lupin (India)
• Huadong Medicine Co., Ltd. (China)
• Viatris Inc. (U.S.)
• Glenmark Pharmaceuticals Inc. (India)
• LEO Pharma Inc. (Denmark)
• AbbVie Inc. (U.S.)
• SANDOZ (Switzerland)
• Teva Pharmaceutical Industries Ltd. (Israel)
• RPG Life Sciences Limited (India)
• Dr. Reddy’s Laboratories Ltd. (India)
• Biocon (India)
• Sun Pharmaceutical Industries Ltd. (India)

ページTOPに戻る

Table of Contents

TABLE OF CONTENTS
1 INTRODUCTION 40
1.1 OBJECTIVES OF THE STUDY 40
1.2 MARKET DEFINITION 40
1.3 OVERVIEW OF THE ASIA-PACIFIC CALCINEURIN INHIBITORS MARKET 40
1.4 CURRENCY AND PRICING 42
1.5 LIMITATIONS 42
1.6 MARKETS COVERED 42
2 MARKET SEGMENTATION 46
2.1 MARKETS COVERED 46
2.2 GEOGRAPHICAL SCOPE 47
2.3 YEARS CONSIDERED FOR THE STUDY 48
2.4 DBMR TRIPOD DATA VALIDATION MODEL 49
2.5 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 52
2.6 MULTIVARIATE MODELLING 53
2.7 DBMR MARKET POSITION GRID 54
2.8 VENDOR SHARE ANALYSIS 55
2.9 SECONDARY SOURCES 56
2.10 ASSUMPTIONS 56
3 EXECUTIVE SUMMARY 57
4 PREMIUM INSIGHTS 62
4.1 PORTER’S FIVE FORCES 63
4.2 PESTEL ANALYSIS 64
5 APAC DEPRESSION SCREENING MARKET: REGULATIONS 65
5.1 REGULATORY AUTHORITIES IN NORTH AMERICA. 65
5.1.1 U.S. FOOD AND DRUG ADMINISTRATION (FDA) 65
5.1.2 HEALTH CANADA 66
5.1.3 FEDERAL COMMISSION FOR THE PROTECTION AGAINST SANITARY RISKS (COFEPRIS) - MEXICO 66
5.2 REGULATORY AUTHORITIES IN EUROPE. 67
5.2.1 GERMANY: 67
5.2.2 UNITED KINGDOM: 67
5.2.3 FRANCE: 67
5.2.4 ITALY: 67
5.2.5 SPAIN: 67
5.3 REGULATORY AUTHORITIES IN ASIA-PACIFIC. 68
5.3.1 JAPAN: 68
5.3.2 CHINA: 68
5.3.3 INDIA: 68
5.3.4 SOUTH KOREA: 68
5.3.5 AUSTRALIA: 69
5.4 REGULATORY AUTHORITIES IN MIDDLE EAST AND AFRICA. 69
5.4.1 SAUDI ARABIA: 69
5.4.2 UNITED ARAB EMIRATES (UAE): 69
5.4.3 EGYPT: 69
5.4.4 SOUTH AFRICA: 69
5.5 REGULATORY AUTHORITIES IN SOUTH AMERICA. 70
5.5.1 BRAZIL: 70
5.5.2 ARGENTINA: 70
5.5.3 COLOMBIA: 70
5.5.4 CHILE: 70
6 MARKET OVERVIEW 72
6.1 DRIVERS 74
6.1.1 RISING PREVALENCE OF AUTOIMMUNE DISEASES 74
6.1.2 INCREASING TRANSPLANTATION PROCEDURES 74
6.1.3 ADVANCEMENTS IN MEDICAL TECHNOLOGY 75
6.1.4 GOVERNMENT SUPPORT & FUNDING FOR TRANSPLANTS 76
6.2 RESTRAINTS 77
6.2.1 LIMITED EFFICACY FOR LONG-TERM USE OF CALCINEURIN INHIBITORS. 77
6.2.2 AVAILABILITY OF ALTERNATIVE IMMUNOSUPPRESSIVE THERAPIES. 77
6.3 OPPORTUNITIES 78
6.3.1 GROWING DEMAND FOR PERSONALIZED MEDICINE 78
6.3.2 GROWING GERIATRIC POPULATION 79
6.3.3 ADVANCEMENTS IN DRUG DELIVERY 79
6.4 CHALLENGES 80
6.4.1 COMPLEX DOSING AND MONITORING 80
6.4.2 HIGH COSTS 80
7 ASIA-PACIFIC CALCINEURIN INHIBITORS MARKET, BY DRUGS 81
7.1 OVERVIEW 82
7.2 TACROLIMUS 85
7.2.1 GENERIC 85
7.2.2 BRANDED 86
7.2.2.1 PROGRAF 86
7.2.2.2 ASTAGRAF XL 86
7.2.2.3 ENVARSUS XR 86
7.2.2.4 OTHER 86
7.2.2.4.1 CAPSULES 86
7.2.2.4.2 TABLETS 86
7.2.2.4.3 INJECTIONS 87
7.2.2.4.4 GRANULES FOR ORAL SUSPENSION 87
7.2.2.4.4.1 1 MG 87
7.2.2.4.4.2 0.5 MG 87
7.2.2.4.4.3 5 MG 87
7.2.2.4.4.4 OTHERS 87
7.2.2.4.4.5 ADULT 88
7.2.2.4.4.6 GERIATRIC 88
7.2.2.4.4.7 PEDIATRIC 88
7.3 CYCLOSPORINE 88
7.3.1 GENERIC 88
7.3.2 BRANDED 89
7.3.2.1 NEORAL 89
7.3.2.2 SANDIMMUNE 89
7.3.2.3 GENGRAF 89
7.3.2.4 OTHERS 89
7.3.2.4.1 CAPSULES 90
7.3.2.4.2 ORAL SOLUTION 90
7.3.2.4.3 INJECTION 90
7.3.2.4.4 OTHERS 90
7.3.2.4.4.1 100 MG 90
7.3.2.4.4.2 25 MG 90
7.3.2.4.4.3 50 MG 90
7.3.2.4.4.4 OTHERS 90
7.3.2.4.4.5 ADULT 91
7.3.2.4.4.6 PEDIATRIC 91
7.3.2.4.4.7 GERIATRIC 91
7.4 PIMECROLIMUS (TOPICAL CREAM) 91
7.4.1 GENERIC 91
7.4.2 BRANDED 91
7.4.2.1 ADULT 92
7.4.2.2 GERIATRIC 92
7.4.2.3 PEDIATRIC 92
7.5 VOCLOSPORIN (ORAL CAPSULE) 92
7.6 OTHERS 93
7.6.1 GENERIC 93
7.6.2 BRANDED 93
8 ASIA-PACIFIC CALCINEURIN INHIBITORS MARKET, BY DRUG TYPE 94
8.1 OVERVIEW 95
8.2 GENERIC 98
8.2.1 POSTOPERATIVE IMMUNOSUPPRESSION 98
8.2.2 ATOPIC DERMATITIS 98
8.2.3 ULCERATIVE COLITIS 98
8.2.4 PSORIASIS 99
8.2.5 KERATOCONJUNCTIVITIS 99
8.2.6 OTHERS 99
8.3 BRANDED 99
8.3.1 POSTOPERATIVE IMMUNOSUPPRESSION 100
8.3.2 ATOPIC DERMATITIS 100
8.3.3 ULCERATIVE COLITIS 100
8.3.4 PSORIASIS 100
8.3.5 KERATOCONJUNCTIVITIS 100
8.3.6 OTHERS 100
9 ASIA-PACIFIC CALCINEURIN INHIBITORS MARKET, BY APPLICATION 101
9.1 OVERVIEW 102
9.2 POSTOPERATIVE IMMUNOSUPPRESSION 105
9.3 ATOPIC DERMATITIS 105
9.4 ULCERATIVE COLITIS 106
9.5 PSORIASIS 106
9.6 KERATOCONJUNCTIVITIS 107
9.7 OTHERS 107
10 ASIA-PACIFIC CALCINEURIN INHIBITORS MARKET, BY ROUTE OF ADMINISTRATION 108
10.1 OVERVIEW 109
10.2 ORAL 112
10.2.1 CAPSULE 112
10.2.2 TABLET 112
10.2.3 SOLUTION 112
10.3 TOPICAL 113
10.4 PARENTERAL 113
10.5 OTHERS 114
11 ASIA-PACIFIC CALCINEURIN INHIBITORS MARKET, BY END USER 115
11.1 OVERVIEW 116
11.2 HOSPITALS 119
11.3 SPECIALTY CLINICS 120
11.4 HOME HEALTHCARE 120
11.5 ACADEMIC AND RESEARCH INSTITUTES 121
11.6 OTHERS 121
12 ASIA-PACIFIC CALCINEURIN INHIBITORS MARKET, BY DISTRIBUTION CHANNEL 122
12.1 OVERVIEW 123
12.2 HOSPITAL PHARMACY 126
12.3 RETAIL PHARMACY 126
12.4 ONLINE PHARMACY 127
12.5 OTHERS 127
13 ASIA-PACIFIC CALCINEURIN INHIBITOR MARKET, BY REGION 128
13.1 ASIA-PACIFIC 130
14 ASIA-PACIFIC CALCINEURIN INHIBITORS MARKET, COMPANY LANDSCAPE 227
14.1 COMPANY SHARE ANALYSIS: ASIA-PACIFIC
15 SWOT ANALYSIS 228
16 COMPANY PROFILES 229
16.1 ASTELLAS PHARMA US, INC. 229
16.1.1 COMPANY SNAPSHOT 229
16.1.2 REVENUE ANALYSIS 230
16.1.3 COMPANY SHARE ANALYSIS 230
16.1.4 PRODUCT PORTFOLIO 231
16.1.5 RECENT DEVELOPMENT 231
16.2 CHUNGHWA CHEMICAL SYNTHESIS & BIOTECH CO., LTD 232
16.2.1 COMPANY SNAPSHOT 232
16.2.2 REVENUE ANALYSIS 232
16.2.3 COMPANY SHARE ANALYSIS 233
16.2.4 PRODUCT PORTFOLIO 233
16.2.5 RECENT DEVELOPMENT 233
16.3 LUPIN 234
16.3.1 COMPANY SNAPSHOT 234
16.3.2 REVENUE ANALYSIS 234
16.3.3 COMPANY SHARE ANALYSIS 235
16.3.4 PRODUCT PORTFOLIO 235
16.3.5 RECENT DEVELOPMENT 235
16.4 HUADONG MEDICINE CO.,LTD 236
16.4.1 COMPANY SNAPSHOT 236
16.4.2 REVENUE ANALYSIS 236
16.4.3 COMPANY SHARE ANALYSIS 237
16.4.4 PRODUCT PORTFOLIO 237
16.4.5 RECENT DEVELOPMENT 237
16.5 VIATRIS INC. 238
16.5.1 COMPANY SNAPSHOT 238
16.5.2 REVENUE ANALYSIS 238
16.5.3 COMPANY SHARE ANALYSIS 239
16.5.4 PRODUCT PORTFOLIO 239
16.5.5 RECENT DEVELOPMENT 239
16.6 APOTEX INC. 240
16.6.1 COMPANY SNAPSHOT 240
16.6.2 PRODUCT PORTFOLIO 240
16.6.3 RECENT DEVELOPMENT 240
16.7 ABBVIE INC 241
16.7.1 COMPANY SNAPSHOT 241
16.7.2 REVENUE ANALYSIS 241
16.7.3 PRODUCT PORTFOLIO 242
16.7.4 RECENT DEVELOPMENT 242
16.8 ACCORD HEALTHCARE US. 243
16.8.1 COMPANY SNAPSHOT 243
16.8.2 PRODUCT PORTFOLIO 243
16.8.3 RECENT DEVELOPMENT 243
16.9 ACTIZAPHARMA 244
16.9.1 COMPANY SNAPSHOT 244
16.9.2 PRODUCT PORTFOLIO 244
16.9.3 RECENT DEVELOPMENT 245
16.10 ADVACARE PHARMA 246
16.10.1 COMPANY SNAPSHOT 246
16.10.2 PRODUCT PORTFOLIO 246
16.10.3 RECENT DEVELOPMENT 246
16.11 BIOCON 247
16.11.1 COMPANY SNAPSHOT 247
16.11.2 REVENUE ANALYSIS 247
16.11.3 PRODUCT PORTFOLIO 248
16.11.4 RECENT DEVELOPMENT 248
16.12 BAUSCH HEALTH COMPANIES INC. 249
16.12.1 COMPANY SNAPSHOT 249
16.12.2 REVENUE ANALYSIS 249
16.12.3 PRODUCT PORTFOLIO 250
16.12.4 RECENT DEVELOPMENT 250
16.13 CONCORD BIOTECH 251
16.13.1 COMPANY SNAPSHOT 251
16.13.2 REVENUE ANALYSIS 251
16.13.3 PRODUCT PORTFOLIO 252
16.13.4 RECENT DEVELOPMENT 252
16.14 DR. REDDY’S LABORATORIES 253
16.14.1 COMPANY SNAPSHOT 253
16.14.2 REVENUE ANALYSIS 253
16.14.3 PRODUCT PORTFOLIO 254
16.14.4 RECENT DEVELOPMENT 254
16.15 GLENMARK PHARMACEUTICALS INC 255
16.15.1 COMPANY SNAPSHOT 255
16.15.2 REVENUE ANALYSIS 255
16.15.3 PRODUCT PORTFOLIO 256
16.15.4 RECENT DEVELOPMENT 256
16.16 LEO PHARMA INC. 257
16.16.1 COMPANY SNAPSHOT 257
16.16.2 PRODUCT PORTFOLIO 257
16.16.3 RECENT DEVELOPMENT 257
16.17 LIPELLA PHARMACEUTICALS, INC. 258
16.17.1 COMPANY SNAPSHOT 258
16.17.2 REVENUE ANALYSIS 258
16.17.3 PRODUCT PORTFOLIO 259
16.17.4 RECENT DEVELOPMENT 259
16.18 NOVARTIS AG 260
16.18.1 COMPANY SNAPSHOT 260
16.18.2 REVENUE ANALYSIS 260
16.18.3 PRODUCT PORTFOLIO 261
16.18.4 RECENT DEVELOPMENT 261
16.19 NOVALIQ GMBH 262
16.19.1 COMPANY SNAPSHOT 262
16.19.2 PRODUCT PORTFOLIO 262
16.19.3 RECENT DEVELOPMENT 262
16.20 PANACEA BIOTEC 263
16.20.1 COMPANY SNAPSHOT 263
16.20.2 REVENUE ANALYSIS 263
16.20.3 PRODUCT PORTFOLIO 264
16.20.4 RECENT DEVELOPMENT 266
16.21 PADAGIS 267
16.21.1 COMPANY SNAPSHOT 267
16.21.2 PRODUCT PORTFOLIO 267
16.21.3 RECENT DEVELOPMENT 267
16.22 RPG LIFE SCIENCES LIMITED 268
16.22.1 COMPANY SNAPSHOT 268
16.22.2 REVENUE ANALYSIS 268
16.22.3 PRODUCT PORTFOLIO 269
16.22.4 RECENT DEVELOPMENT 269
16.23 VELOXIS PHARMACEUTICALS, INC. 270
16.23.1 COMPANY SNAPSHOT 270
16.23.2 REVENUE ANALYSIS 270
16.23.3 PRODUCT PORTFOLIO 270
16.23.4 RECENT DEVELOPMENT 270
16.24 ZHAOKE OPHTHALMOLOGY LIMITED 271
16.24.1 COMPANY SNAPSHOT 271
16.24.2 REVENUE ANALYSIS 271
16.24.3 PRODUCT PORTFOLIO 272
16.24.4 RECENT DEVELOPMENT 272
16.25 ZAMBON COMPANY S.P.A. 273
16.25.1 COMPANY SNAPSHOT 273
16.25.2 PRODUCT PORTFOLIO 273
16.25.3 RECENT DEVELOPMENT 274
17 QUESTIONNAIRE 275
18 RELATED REPORTS 278